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Soluble Amyloid-beta Aggregates 
from Human Alzheimer’s Disease 
Brains
Thomas J. Esparza1, Norelle C. Wildburger1, Hao Jiang1, Mihika Gangolli2, Nigel J. Cairns1,3,4, 
Randall J. Bateman1,3,4 & David L. Brody1,2,4
Soluble amyloid-beta (Aβ) aggregates likely contribute substantially to the dementia that characterizes 
Alzheimer’s disease. However, despite intensive study of in vitro preparations and animal models, little 
is known about the characteristics of soluble Aβ aggregates in the human Alzheimer’s disease brain. 
Here we present a new method for extracting soluble Aβ aggregates from human brains, separating 
them from insoluble aggregates and Aβ monomers using differential ultracentrifugation, and purifying 
them >6000 fold by dual antibody immunoprecipitation. The method resulted in <40% loss of starting 
material, no detectible ex vivo aggregation of monomeric Aβ, and no apparent ex vivo alterations in 
soluble aggregate sizes. By immunoelectron microscopy, soluble Aβ aggregates typically appear as 
clusters of 10–20 nanometer diameter ovoid structures with 2-3 amino-terminal Aβ antibody binding 
sites, distinct from previously characterized structures. This approach may facilitate investigation 
into the characteristics of native soluble Aβ aggregates, and deepen our understanding of Alzheimer’s 
dementia.
Clinically defined dementia of the Alzheimer’s type (DAT) is the most common cause of age-related progressive 
cognitive dysfunction. Post-mortem, pathologically defined Alzheimer’s disease (AD) is present in the major-
ity of patients diagnosed during life with DAT. The ‘Amyloid Cascade Hypothesis’, a leading idea regarding the 
cause of DAT, is derived from genetic studies of both age-related and familial early onset disease, both of which 
implicate increased production and aggregation of the Aβ peptide1,2. Thus, Aβ has been the major target for 
disease-modifying therapeutic development. However, the extent of Aβ deposition correlates only modestly with 
dementia; many middle aged and elderly people have extensive plaque deposition without any signs of demen-
tia3–7. Furthermore, Aβ deposition begins decades before the onset of dementia8.
In recent years, water-soluble Aβ aggregates (varyingly termed Aβ oligomers, amyloid derived diffusible lig-
ands, Aβ *56, amylospheroids, annular protofibrils, and other appellations) have been implicated more directly 
in causing synaptic dysfunction and neuronal cell death in vitro9–16 as well as impaired behavioral performance 
in animal models17–19. Soluble Aβ aggregates have been detected in human brain lysates from AD patients15,20–35. 
However, these aggregates are highly heterogeneous15,23,24,26–28,32,35–39, and it is unclear whether the characteristics 
of the soluble Aβ aggregates in the human brain are similar to the soluble Aβ aggregates in animal models or in 
vitro preparations37. Of note, native human brain soluble Aβ aggregates are orders of magnitude more toxic than 
similar size synthetic aggregates24,27. Furthermore, determining the relationship between human patients and ani-
mal models is of vital importance because to date, Aβ -targeted therapeutics developed using these animal models 
have not been successful at reversing DAT or altering disease progression.
Our group reported development of a sensitive, specific, quantitative, and high-throughput assay for soluble 
Aβ aggregates40 (termed ‘oligomers’ in that publication). The assay uses the monoclonal antibody HJ3.4 which 
is specific for the canonical N-terminus of Aβ 40; it does not recognize amyloid precursor protein, unlike other 
commonly used antibodies such as 6E10 or 4G8. Using this assay, we were able to fully distinguish between DAT 
patients and high pathology non-demented controls with no overlap between groups based on the ratio of soluble 
Aβ aggregates to plaque area40.
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However, a major challenge has been that the specific forms of soluble Aβ aggregates most relevant to human 
disease have not been determined. Aβ can potentially aggregate into a vast number of forms, consisting of dif-
ferent numbers of Aβ peptides, various size forms of Aβ , multiple Aβ post-translational modifications and alter-
native structural configurations of Aβ . It has not been clear which of these aggregation forms are most relevant 
to AD. Here we report a method to purify soluble Aβ aggregates directly from frozen human AD brain tissue, 
reasoning this would be the most relevant source for the species directly underlying dementia in humans.
Results
Our approach to isolating soluble Aβ aggregates from human brain involved tissue homogenization, differential 
ultracentrifugation, and dual antibody immunoprecipitation (Fig. 1). During the methods development phase, 
we broke the problem down into three tasks: 1) Maximizing extraction of soluble Aβ aggregates from human 
Alzheimer’s disease brain tissue; 2) Isolating the soluble Aβ aggregates from other forms of Aβ ; 3) Separating the 
soluble Aβ aggregates from other proteins.
We tested multiple different methods to address each of these tasks, and used four criteria to quantitatively 
assess the overall results: 1) Quantitative completeness of separation of the soluble Aβ aggregates from soluble 
monomers and insoluble aggregates; 2) Fold enrichment of Aβ compared to total protein; 3) Quantitative com-
pleteness of the recovery of the soluble Aβ aggregates present in the starting material, i.e. minimization of loss 
during purification; and 4) Minimization of ex vivo aggregation or disaggregation of Aβ during the extraction 
and purification process.
For quantification of soluble Aβ aggregates at each step of the process, we used a 96 well plate-based assay 
(Supplementary Fig. 1A) modified from our previously reported 384 well plate assay40. The soluble Aβ aggregate 
assay uses the same antibody, HJ3.4, to capture and detect Aβ . Monomeric Aβ is captured but not detected due to 
epitope masking by the capture antibody. For quantitation, the assay uses synthetic Aβ dimers, so the quantitative 
units are ‘dimer equivalents’ even though the assay measures soluble aggregates of many sizes. This assay has a 
lower limit of quantitative reliability of 31.25 pg/mL dimer equivalents and an approximately 100-fold dynamic 
range. It is relatively high throughput, such that a single investigator can run up to 6 plates per day. However it 
only recognizes aggregates with ≥ 2 free canonical N-termini and thus should be considered an assay for just this 
class of soluble Aβ aggregates. At each step of the process, we also quantified total Aβ with a free N-terminus 
(Aβ 1−x) using a different 96 well plate-based ELISA with HJ5.1, a mid-domain Aβ antibody, as the capture anti-
body and HJ3.4 as the detection antibody (Supplementary Fig. 1B).
Extraction of soluble Aβ aggregates. We tested a variety of single extraction, serial extraction and 
detergent-enhanced extraction methods. We determined that a single extraction by dounce homogenization 
in phosphate buffered saline (PBS) plus a sub-critical micelle concentration (0.45% weight/volume) of the 
zwitterionic detergent [(3-Cholamidopropyl)dimethylammonio]-1-Propanesulfonate (CHAPS) was appro-
priate. PBS + 0.45% CHAPS extraction yielded nearly 2-fold higher concentrations of soluble Aβ aggregates 
than extraction in PBS alone, and more than PBS + 4 other detergents at sub-critical micelle concentrations 
(Supplementary Fig. 2A). Furthermore, while a second extraction in PBS alone yielded 36% additional soluble 
Aβ aggregates after the first extraction, a second extraction in PBS+ 0.45% CHAPS yielded only 15% additional 
soluble Aβ aggregates and subsequent extractions yielded very little additional soluble Aβ aggregate, indicating 
efficient first pass extraction in PBS + 0.45% CHAPS (Supplementary Fig. 2B–D). Notably, even after 5 extrac-
tions in PBS + 0.45% CHAPS, additional Aβ could be extracted in 0.5 M Guanidine (Supplementary Fig. 2C). 
Taken together, these results were consistent with the material in the first PBS + 0.45% CHAPS extraction repre-
senting efficient extraction of a finite pool of soluble Aβ aggregates but not consistent with extraction of normally 
insoluble Aβ from plaques.
Importantly, extraction in PBS + 0.45% CHAPS did not result in ex vivo aggregation of monomeric Aβ . 
We isolated native monomeric Aβ from human Alzheimer’s disease (CDR3) brain tissue (Fig. 1), then added 
the AD-derived monomer (2 ng/mL) to the buffer during the homogenization of cognitively normal, AD 
Figure 1. Method for isolating and purifying soluble Aβ aggregates from human AD brain. Cortical tissue 
was dounce homogenized in sub-critical micelle concentration of the detergent CHAPS, size forms of Aβ were 
isolated by differential ultracentrifugation, then Aβ was purified by dual antibody immunoprecipitation and 
elution in ammonium hydroxide. RCF: relative centrifugal force. Sol.: soluble, LMW: low molecular weight, 
HMW: high molecular weight. IP: immunoprecipitation.
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pathology-negative human brain tissue in the presence of sub-critical micelle concentrations of CHAPS. The 
homogenates were centrifuged at 100,000× g prior to assessment using the dimer equivalent ELISA. We observed 
no ELISA signal at each concentration, indicating that 0.45% CHAPS did not induce ex vivo formation of sol-
uble Aβ aggregates within the level of detection (Fig. 2A). Furthermore, there were no soluble Aβ aggregates 
detected after 475,000× g RCF ultracentrifugation (Fig. 2B–D). We repeated this control experiment using syn-
thetic Aβ 1-42 and found no effect of 0.45% CHAPS on soluble Aβ aggregate formation as a function of concen-
tration of synthetic Aβ 1-42 up to 20 ng/mL (Supplementary Fig. 3). In contrast, the commonly used detergent 
sodium dodecyl sulfate (SDS) dramatically enhanced ex vivo aggregation of Aβ at concentrations of 0.2% or 
higher (Supplementary Fig. 4), which may be relevant for interpretation of results from other groups that used 
this detergent in the context of polyacrylamide gel electrophoresis (see Supplementary Discussion). Triton X-100 
also caused some ex vivo aggregation at 1%, but Tween-20 did not affect aggregation at concentrations up to 1% 
(Supplementary Fig. 4). In summary, we found that a single extraction in PBS + 0.45% CHAPS provided a high 
yield of soluble Aβ aggregates from human brain tissue without causing detectible ex vivo aggregation, but other 
detergents such as SDS and Triton X-100 appeared to cause ex vivo aggregation.
Minimizing non-specific loss of Aβ. It became clear during our investigations of soluble Aβ aggregate 
extractions that the quantities of these aggregates were not stable over time; there was a rapid loss of Aβ aggre-
gates, likely due to nonspecific binding to surfaces. Even low-protein binding tubes and tips did not eliminate 
this loss. We therefore modified our technique to include blocking of every tube and every pipet tip with a 1% 
bovine serum albumin (BSA) solution. With BSA blocking, non-specific loss was dramatically reduced both at 
room temperature and 4 °C (Supplementary Fig. 5). BSA blocking reduced loss of Aβ but had no apparent effect 
on the size exclusion chromatography profile of Aβ in human brain lysates (Supplementary Fig. 6). Without albu-
min blocking, we estimate that > 90% of all Aβ aggregates would have been lost during even our most efficient 
purification protocols.
Isolation of soluble Aβ aggregates from other forms of Aβ. For the second task, separating soluble 
Aβ aggregates from other forms of Aβ , we used a differential ultracentrifugation protocol. By definition, solubi-
lizing the preparation in PBS separates ‘soluble’ forms of Aβ from ‘insoluble’ forms of Aβ . We pelleted the less 
soluble forms of Aβ by centrifugation at 100,000× g (Fig. 1). Subsequent experiments demonstrated that the 
forms of Aβ in the 100,000× g pellet were morphologically distinct from the more soluble forms of Aβ present in 
the 100,000× g supernatant (see Fig. 6, below).
Previously40, we demonstrated using size exclusion chromatography that the soluble Aβ aggregates extracted 
from human brain detected by our assay were large, eluting close to the void volume in fractions 7–10 near 
the 670 kDa globular protein size standard on a Superdex 200 column (Fig. 3A–C). In contrast, monomeric Aβ 
is ~4 kDa in size, eluting in fractions 19–21. We therefore considered using size exclusion chromatography to 
separate soluble Aβ aggregates from monomers, but found that this method was inefficient for scale-up because 
size exclusion chromatography performed poorly for large liquid volumes. We lysed each gram of brain in 10 mL 
of buffer whereas only 1 mL at a time could be run on size exclusion chromatography. We next considered the 
use of molecular weight cutoff centrifuge filters, but found that there was substantial loss of soluble Aβ aggre-
gates during this process and that it did not efficiently remove low molecular weight species from the retentate 
(Supplementary Fig. 7). Third, we considered ammonium sulfate precipitation of high molecular weight aggre-
gates. This method scaled up well, did not result in substantial loss of soluble Aβ aggregates, and did not induce 
ex vivo aggregation of monomeric Aβ , but it did not fully separate soluble Aβ aggregates from endogenous mon-
omeric Aβ (Supplementary Fig. 8). Finally, we turned to differential ultracentrifugation and found that 1 hour at 
475,000× g kept monomeric Aβ in the upper phase and pelleted the soluble Aβ aggregates. Because the soluble 
Figure 2. Sub-critical micelle concentration of CHAPS in PBS does not induce ex vivo aggregation of 
human AD brain derived Aβ monomers. (A) Titration of CHAPS during homogenization of normal control 
cortical tissue spiked with 2 ng/mL human AD brain-derived Aβ monomer. No induction of detectible Aβ 
aggregates. (B–D). Size exclusion chromatography of the 475,000× g RCF sucrose cushion fraction from 
normal control cortical tissue spiked with 2 ng/mL AD brain-derived Aβ monomer. (B) Total protein, (C) 
Soluble Aβ aggregate assay indicating no detectible Aβ aggregates, (D) Aβ 1−x assay indicating < 10% of spiked 
monomer present in sucrose cushion (high molecular weight enriched) portion of the preparation. LoQ: limit 
of quantitation.
www.nature.com/scientificreports/
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Aβ aggregates were difficult to completely resuspend after pelleting at 475,000× g, we modified the 475,000× g 
ultracentrifugation protocol to include a 70% sucrose cushion, allowing nearly complete recovery of the soluble 
Aβ aggregates. The Aβ in the 475,000× g sucrose cushion was essentially all high molecular weight with nearly 
undetectable low molecular weight Aβ (Fig. 3D–F). In a complementary fashion, the Aβ in the 475,000× g super-
natant fraction was entirely low molecular weight (Fig. 4). This method could be applied to up to 8 tubes at a time 
with 26 mL of material per tube. These results confirmed that differential ultracentrifugation was an effective and 
scalable method to separate soluble Aβ aggregates from other forms of Aβ .
Separation of soluble Aβ aggregates from other proteins. For the third task, separating soluble 
Aβ aggregates from other proteins, we considered immunoprecipitation, ion exchange chromatography, and 
Figure 3. Enrichment and preservation of soluble high molecular weight Aβ aggregates from human AD 
brain following differential centrifugation and immunoprecipitation. (A) Size exclusion chromatography 
(SEC) total protein profile (measured by absorption) of a CDR3 tissue homogenate prepared in 1xPBS 
containing 0.45% CHAPS; overlay with Bio-Rad gel filtration standards (red) with molecular weight in kDa 
indicated (red text). (B,C). Soluble Aβ aggregate and Aβ 1−x assays on SEC fractions of original lysates. LoQ: 
limit of quantitation. (D) SEC total protein profile of the sucrose cushion fraction after ultracentrifugation at 
475,000× g. (E,F) Soluble Aβ aggregate and Aβ 1−x assays on SEC fractions of sucrose cushion fraction after 
ultracentrifugation at 475,000× g, demonstrating the preservation of soluble Aβ aggregates and separation 
from monomers. (G) SEC total protein profile (measured by NanoOrange) of the 475,000× g sucrose cushion 
fraction followed by immunoprecipitation (IP), washing, and elution with ammonium hydroxide. (H,I) Soluble 
Aβ aggregate and Aβ 1−x assays on eluted high molecular weight soluble Aβ aggregates. Insets: Quantification of 
protein (note log scale in panel G), soluble Aβ aggregates, and Aβ 1−x in the immunoprecipitation bead washes.
www.nature.com/scientificreports/
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hydrophobicity chromatography; we settled on a dual antibody immunoprecipitation with ammonium hydrox-
ide elution as the final method.
Ion exchange chromatography with strong anion and strong cation exchangers at neutral and basic pH’s were 
tested (acidic pH’s were avoided to prevent passing Aβ through its pKa at ~5.5). Anion exchange chromatography 
at pH 8 yielded a discrete soluble Aβ aggregate peak (Supplementary Fig. 9A,B) but only a 3.1 fold enrichment 
of soluble Aβ aggregates compared with total protein. The peak occurred over 14 mL, resulting in substantial 
dilution.
Hydrophobicity interaction chromatography with several resins (butyl sepharose, phenyl sepharose, and octyl 
sepharose) and several mobile phases (sodium chloride, ammonium sulfate, sodium sulfate) was tested. No clear 
enrichment of soluble Aβ aggregates was obtained, and the soluble Aβ aggregates eluted over a broad range of salt 
concentrations (Supplementary Fig. 9C,D).
Figure 4. Aβ monomer is the predominant size form of Aβ from human AD brain in the top layer after 
475,000× g ultracentrifugation. (A) SEC total protein profile from 1 mL of the top 5 mL supernatant layer 
removed following ultracentrifugation at 475,000× g. (B) Aβ 1−x assay on the same supernatant SEC fractions.
Figure 5. “Quantitative bookkeeping”. Total protein and soluble Aβ aggregate assays (note log scale) 
performed on each step of the isolation and purification of soluble Aβ aggregates from human AD brain.
www.nature.com/scientificreports/
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Immunoprecipitation using beads conjugated with two different monoclonal antibodies recognizing two dis-
tinct epitopes was used to increase avidity. We used HJ3.4 recognizing the canonical free Aβ N-terminus, and 
HJ5.1 recognizing a mid-domain epitope conjugated directly to cyanogen bromide sepharose beads. Incubation 
of brain lysates overnight at 4 °C with these dual antibody conjugated beads resulted in a complete immuno-
depletion of Aβ ; no detectible Aβ was present in the supernatant. Elution in the detergent lithium docecyl sulfate 
(LDS) at 95 °C dramatically altered the size forms of Aβ , elution in the high salt buffer 5 M lithium chloride 
resulted in incomplete recovery, and elution in acidic conditions with 200 mM glycine pH 2.7 resulted in almost 
no recovery (Supplementary Fig. 10A–C). In contrast, elution in 150 mM ammonium hydroxide pH 10.5 resulted 
in nearly complete recovery of Aβ without changing the size forms resolved on size exclusion chromatography 
(Supplementary Fig. 10D). Immunoprecipitation of the isolated high molecular weight soluble Aβ aggregates 
from the 475,000× g sucrose cushion with these dual antibody beads and elution with ammonium hydroxide 
resulted in a nearly complete recovery of Aβ , a sharpening of the Aβ peak into fractions 8–9, and no change in 
the size forms of Aβ present (Fig. 3G–I). Total protein fell ~1000 fold during the bead washes (Fig. 3G inset), but 
no detectible Aβ was lost in these washes (Fig. 3H,I insets). These results confirmed that dual antibody immuno-
precipitation with ammonium hydroxide elution was an effective method for separating Aβ from other proteins.
Quantitative bookkeeping. We took aliquots from each step during our final purification protocol and 
measured soluble Aβ aggregate concentrations and total protein concentrations for the purposes of quantitative 
bookkeeping. We found that a typical purification protocol resulted in over 6000 fold purification of soluble Aβ 
aggregates relative to total protein and > 60% recovery of the soluble Aβ aggregates present in the original brain 
lysate (Fig. 5). The recovery rate was calculated by measuring the concentration of soluble Aβ aggregates in the 
Figure 6. Immunoelectron microscopic analysis of soluble Aβ aggregates from human AD brain in 
comparison to low molecular weight Aβ and insoluble aggregates. Labeling was performed using the 
anti-Aβ antibody HJ3.4 followed by anti-mouse secondary conjugated to 6 nm diameter gold beads. (A) Exemplar 
immunoelectron microscopic images of low molecular weight (LMW) Aβ immunoprecipitated from the 475,000× g 
supernatant. White arrows indicate individually resolved objects with typically 1 but occasionally 2 gold beads. Scale 
bar = 100 nm. Inset shows a single 6 nm gold bead, with scale bar 10 nm. (B) Exemplar immunoelectron microscopic 
images of soluble high molecular weight (HMW) Aβ aggregates immunoprecipitated from the sucrose cushion 
after 475,000× g ultracentrifugation. Arrows indicate compact aggregates with multiple gold beads. (C) Exemplar 
immunoelectron microscopic images of insoluble high molecular weight Aβ aggregates immunoprecipitated from 
the pellet after 100,000× g ultracentrifugation. Arrows indicate elongated and irregular aggregates with multiple 
gold beads per aggregate. (D) Surface area measurements (in nm2, note log scale) of the gold labeled objects in the 
three fractions: LMW (blue circles), soluble HMW (orange squares), and insoluble (red triangles). Preparations were 
made from 6 AD patients; 10 random fields per patient were analyzed in an automated fashion. (E). Number of gold 
particles per aggregate were counted in an automated fashion from the same images.
www.nature.com/scientificreports/
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initial lysates and the concentration in the final immunoprecipitated and eluted material from the 475,000× g 
sucrose cushion phase. The calculations were corrected for 5–10 microliter aliquots of material taken for anal-
ysis at each step of the purification. The small quantities of soluble Aβ aggregates in the 100,000× g pellet and 
in the 475,000× g supernatant were considered part of the ~40% loss. In 6 distinct preparations from 6 different 
Alzheimer’s disease brain samples with extensive Aβ plaque pathology (Supplementary Fig. 11), we recovered 
approximately 2–6 ng dimer equivalents per gram of brain tissue and were able to enrich soluble Aβ aggregates to 
at least 0.1 to 0.6 percent of total protein (Supplementary Table 1). This enrichment may be a substantial underes-
timate; the actual purification may be substantially higher (see Discussion).
Morphological characteristics of soluble Aβ aggregates. We used immunoelectron microscopy (EM) 
to directly characterize the size and number of Aβ immunoreactive sites per aggregate (Fig. 6). The N-terminal 
specific antibody HJ3.4 was used for these analyses, followed by secondary antibodies conjugated to 6 nm gold 
beads. The three differential ultracentrifugation separated fractions of Aβ were morphologically distinct. The 
material immunoprecipitated from the low molecular weight (475,000× g supernatant) fraction consisted of 
ovoid structures (Fig. 6A), on average ~200 nm in surface area (Fig. 6D), which bound typically exactly 1 but 
occasionally 2 anti-Aβ antibodies, (Fig. 6E). The material immunoprecipitated from the high molecular weight 
soluble Aβ aggregate (475,000× g sucrose cushion) fraction consisted of larger irregular structures (Fig. 6B), with 
median size ~700 nm2 in surface area which bound typically 2-3 anti-Aβ antibodies (range 1–9). The material 
immunoprecipitated from the relatively insoluble high molecular weight (100,000× g pellet) fraction consisted of 
even larger and more elongated structures (Fig. 6C), with median size 2000–29,000 nm2 in surface area and a wide 
range of anti-Aβ antibody binding stoichiometries. Some of the larger aggregates from the insoluble fraction had 
irregular fibrillar mesh-like structures (Supplementary Fig. 12), whereas fibrillar structures were never observed 
in the human brain soluble Aβ aggregate fractions.
Quick-freeze deep etch immuno-EM further revealed that the soluble Aβ aggregates consisted of clusters of 
approximately 10 × 20 nm ovoid substructures, with each ovoid substructure appearing to bind at most 1 anti-Aβ 
antibody (Fig. 7 and Supplementary Fig. 12). Quick-freeze deep etch methods were useful for morphology but 
not optimal for automated quantitative analysis because the intensity of the edges was often similar to the inten-
sity of the gold beads.
There were modest but statistically significant correlations between the area of the soluble high molecular 
weight Aβ aggregates and the number of anti-Aβ antibodies bound (Supplementary Fig. 13). Based on the scatter 
plots of area vs. number of anti-Aβ antibodies bound, there appeared to be two different classes of soluble Aβ 
Figure 7. Quick-freeze deep etch negative replica immunoelectron microscopic images of soluble Aβ 
aggregates from human AD brain. (A,B) Exemplar images of soluble high molecular weight Aβ aggregates 
immunoprecipitated from the sucrose cushion after 475,000× g ultracentrifugation spotted onto glass and 
stained with N-terminal Aβ antibody HJ3.4 followed by anti-mouse secondary conjugated to 6 nm diameter 
gold beads. Replicas were produced by platinum deposition and mounted for imaging. Red arrows indicate 
aggregates with multiple gold bead (white) labeling. Scale bars 100 nm: (C) Images with no primary antibody 
indicating absence of nonspecific binding of gold-labeled secondary antibody. (D,E) Expanded view of 
aggregates from panels A and B with contrast inverted to make the gold bead labels (black) more apparent.
www.nature.com/scientificreports/
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aggregates; those for which there was a very strong linear relationship between area and antibody binding stoi-
chiometry with approximately 200 nm2 per antibody binding, and those for which the area exceeded that which 
could be accounted for by antibody binding stoichiometry. In this second class, a large portion of the surfaces 
of the soluble Aβ aggregates were not immunoreactive with the HJ3.4 antibody. This could indicate additional 
constituents other than HJ3.4 immunoreactive Aβ . The correlation between area of the relatively insoluble high 
molecular weight aggregates and the number of anti-Aβ antibodies bound was very tight (Supplementary Fig. 14), 
as would be expected for a single class of aggregates. There was also a large portion of the surfaces of the relatively 
insoluble aggregates that was not immunoreactive with the HJ3.4 antibody. Synthetic Aβ 1-40 aggregates were more 
densely labeled by HJ3.4, but still not completely saturated with gold particles (Supplementary Fig. 12).
Mass spectrometric analysis of soluble Aβ aggregates. We performed top-down tandem mass spec-
trometry on the soluble Aβ aggregates isolated from human AD brain and detected full length (undigested) Aβ 1-40 
and Aβ 1-42 (Fig. 8 and Supplementary Fig. 15). The mass spectrometry results were very clean, with clear peaks 
within the isotopic envelope spaced every 0.2 daltons, indicating a + 5 charge state. A very large number of frag-
mented ‘b’ ions and ‘y’ ions were detected, yielding a high degree of confidence in the identity of the sequences. 
These results confirm that the soluble Aβ aggregate preparations from human AD brain truly contain Aβ . Many 
other forms of Aβ were also detected (see below.)
Discussion
In summary we have developed a method for reliably enriching soluble Aβ aggregates from human brain tissue, 
separating them from other forms of Aβ , and purifying them more than 6000 fold with less than 40% loss of start-
ing material. These soluble Aβ aggregates are believed to be play a critical role in neurodegeneration relating to 
Figure 8. Mass spectrometry of soluble Aβ aggregates from human AD brain. (A) Liquid chromatography-
tandem mass spectrometry (LC-MS/MS) spectrum for undigested, full-length Aβ 1-40. Each peak represents an 
ion fragmented from Aβ 1-40, with peaks labeled ‘b’ representing N-terminal fragment ions and peaks labeled ‘y’ 
representing C-terminal fragment ions. The numbers indicate measured mass/charge ratio (m/z). The single 
letter amino acid code across the top indicates the de novo sequence identified by mass spectrometry, which 
matches the amyloid precursor protein sequence corresponding to Aβ 1-40. The line breaks between amino acids 
indicate a cleavage of the amide bond between two adjacent amino acids producing fragment ions. The lines 
below each amino acid indicate a detected ‘b’ ion, and lines above indicate a detected ‘y’ ion. Inset: isotopic 
envelope for the + 5 charged, full-length Aβ 1-40: the peaks are spaced 0.2 daltons apart at z = + 5 because the 
naturally occurring isotopes (e.g. 13C and 15N) differ by 1 dalton. For the + 5 ion, the observed m/z was 866.4351 
(theoretical m/z = 866.4370), which was − 2.1 parts per million (ppm) error from the theoretical mass of Aβ 1-40. 
(B) Spectrum for full length Aβ 1-42. For the + 5 ion, the observed m/z was 903.2623 (theoretical m/z = 903.2612), 
which was 1.2 ppm error from the theoretical mass of Aβ 1-42.
www.nature.com/scientificreports/
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dementia of the Alzheimer’s type, however they had not been previously isolated from human brain and purified 
sufficiently for detailed analysis. Our isolation and partial purification was sufficient for immunoelectron micro-
scopic characterization, which indicated that these soluble Aβ aggregates appear to consist of clusters of ovoid, 
non-fibrillar structures typically with 2–3 binding sites for antibodies binding amino-terminal Aβ .
We are in the early stages of fully characterizing the specific Aβ proteoforms present in the soluble Aβ aggre-
gates using top-down (undigested) tandem mass spectrometry. Absolute quantification of the abundance of var-
ious forms of Aβ in the soluble Aβ aggregates has not yet been performed, but is an important area of ongoing 
investigation. A full characterization of the Aβ proteoforms and possible associated proteins is beyond the scope 
of this communication.
Relationship to Previous Studies. The relationship between our findings and those of previous research 
groups investigating soluble Aβ aggregates in human AD brain is complex (please see Supplementary Table 2 
and Supplementary Discussion), but may be explained largely by differences in experimental methods. Our 
results are most similar to those of Noguchi et al., who reported high molecular weight globular assemblies of Aβ 
from Alzheimer’s disease human brain after saline-based homogenization24. In contrast, other investigators have 
reported smaller forms of soluble Aβ assemblies20,23, or assessed partially dissociated aggregates likely derived 
from water insoluble plaques41. Many of the previously reported preparations have involved SDS PAGE to assess 
the size forms, which can both break apart larger Aβ assemblies and cause monomeric Aβ to aggregate ex vivo42. 
A highly cited previous report23 used size exclusion chromatography to assess the size of the soluble Aβ aggre-
gates, but the running buffer was ammonium acetate pH 8.5 which can cause changes in assembly of protein 
complexes43–47. We found that ammonium acetate pH 8.5 consistently changes the apparent size of soluble Aβ 
aggregates (Supplementary Fig. 16), though another recent report using a different assay indicates that it may not 
always do so35. Furthermore, detection of the putative Aβ assemblies often involved antibodies which recognize 
epitopes present in amyloid precursor protein as well as Aβ , such that assemblies of Aβ cannot be distinguished 
unambiguously from fragments of amyloid precursor protein. Thus, although several groups have reported char-
acteristics of soluble human brain Aβ aggregates that differ from those described here, we have demonstrated 
through a careful series of control experiments that our method minimizes many previously concerning potential 
sources of ex vivo aggregation and de-aggregation.
Limitations and Future Directions. The concentrations of soluble Aβ aggregates measured here may be 
underestimates, since our ELISA detects only species with at least 2 free canonical Aβ N-termini (amino acids 
DAEFR… ). Our initial data from mass spectrometric analysis indicate multiple other forms of Aβ with truncated 
and post-translationally modified N-termini48. It is therefore likely that our enrichment of Aβ may be quantita-
tively greater than reported. For the same reason, the number of Aβ peptides per aggregate may also be underes-
timates. Future additional immunoelectron microscopy studies using antibodies recognizing different Aβ species 
will be of interest.
Because the antibody HJ3.4 could also in theory recognize the C99 peptide or C-terminally truncated ver-
sions of this peptide, we cannot be absolutely certain that all of the detected particles represent Aβ . Our mass 
spectrometry results, however, have not yet revealed any peptides longer than 43 amino acids (Wildburger et al., 
in preparation).
It is likely that there are other proteins associated with the soluble Aβ aggregates characterized here; future 
investigations involving discovery based mass-spectrometry and double immunoelectron microscopy validation 
are underway, but are beyond the scope of this report.
We cannot be certain that the sizes of the aggregates and numbers of Aβ binding sites per aggregates represent 
the state of these species in the living human brain. It is possible that post-mortem events such as autolysis could 
have altered these aggregates. Experiments are underway to assess the effects of varying simulated post-mortem 
intervals in transgenic mice. Methods to assess soluble Aβ aggregates in the living human brain are still under 
development. The relationship between soluble Aβ aggregates in the brain and in the cerebrospinal fluid is likely 
to be complex. To date, we and others have not been able to detect soluble Aβ aggregates in human cerebrospinal 
fluid40,49, though some groups have done so50–52. Assessments of brain biopsy tissue from patients undergoing 
normal pressure hydrocephalus surgery, nearly half of whom may also have Aβ pathology53, represent a logical 
direction for addressing potential post-mortem artifacts. Direct detection in the brain using molecularly specific 
electrode technology may represent a novel approach54.
We also cannot be certain of whether changes in the properties of the soluble Aβ aggregates occurred during 
purification. The consistent size profile of the aggregates from raw lysates to finale eluates following immunopre-
cipitation indicate that there were no gross changes, but more subtle effects such as loss of low molecular weight 
components cannot be ruled out. Likewise, the addition of exogenous monomeric Aβ as a control for artifactual 
aggregation would not be expected to mimic effects on intracellular Aβ . Selective binding to EM grids could also 
have biased our observations. We cannot fully exclude a shift in apparent size of soluble Aβ aggregates due to 
interaction with the matrix during SEC. However, synthetic Aβ monomer and synthetic Aβ dimer run true to size 
under identical SEC conditions40. Furthermore, the large size observed by SEC is generally concordant with the 
immuno-EM observations, though at present it is not possible to directly estimate the molecular weight of the 
soluble Aβ aggregates from the EM observations. A future direction will involve orthogonal biophysical charac-
terization of the aggregates from raw lysates vs. final eluates based on charge (ion exchange) and hydrophobicity 
(HIC). The quantities of soluble Aβ aggregates we have extracted are as yet too low to allow dynamic light scatter-
ing, circular dichroism, or fast photochemical oxidation of protein- mass spectrometry.
The Aβ species described here may be just one of many classes of soluble Aβ aggregates. Other classes of 
aggregates that do not bind HJ3.4 would not be detected or characterized. Thus, a priority for future research will 
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be a broader exploration of the spectrum of Aβ aggregates present in the human AD brain using other detection 
reagents (see Supplementary Discussion).
Importantly, the physiological effects of the soluble Aβ aggregates isolated and partially purified using these 
methods has not been characterized. In previous studies, low molecular weight soluble Aβ aggregates derived 
from human brain potently impaired synaptic plasticity in rodent brain slices23 and caused tau hyperphospho-
rylation with morphological disruption in cultured neurons27. However, it was reported that the high molecular 
weight soluble Aβ aggregates after size exclusion chromatography in ammonium acetate did not affect synaptic 
plasticity23. High molecular weight human brain aggregates separated in saline have been reported to cause toxic-
ity in cultured neurons24. The relationship between these relatively acute in vitro physiological effects and slowly 
progressive dementia of the Alzheimer’s type has yet to be determined. Underscoring the relevance of this line 
of investigation is the finding that the levels of soluble Aβ aggregates in lysates from human brain were strongly 
related to dementia status, and fully differentiated demented from non-demented individuals after normalizing 
for Aβ plaque burden40.
Implications. We anticipate that the method presented here for extracting, isolating, and purifying soluble 
Aβ aggregates will facilitate many additional investigations of the properties of these aggregates. One of the major 
long-term goals of this line of investigation is to discover the distinguishing structural characteristics of the most 
relevant forms of soluble Aβ aggregates from the human brain. The specific details of their molecular compo-
sition will be of great interest with regard to developing specific candidate therapeutics to prevent their forma-
tion, enhance their clearance, or block their effects. Direct measurements of these soluble Aβ aggregates in living 
humans using biofluids or by molecular imaging could then be used for pharmacodynamic characterization of 
candidate therapeutics. Importantly, the extent to which the soluble Aβ aggregates present in the human brain is 
similar to or different from the aggregates present in animal models of AD-like pathology is entirely unknown, but 
critical for the field of therapeutic development. If one or more animal models faithfully recapitulates the soluble 
Aβ aggregates present in humans, it would seem logical to use these models for therapeutic development rather 
than other models that do not accurately recapitulate the human-like aggregates. Thus, characterizing a range of 
animal models of AD-like pathology is a top priority. It is possible, however, that none of the existing animal mod-
els accurately recapitulate human soluble Aβ aggregates, and that new model systems will need to be developed55.
Furthermore, the purification scheme developed here may be thought of as a generalizable framework for 
assessment of proteins aggregates relevant to human neurodegenerative diseases. Soluble aggregates of tau, alpha 
synuclein, prion protein, TAR DNA-binding protein 43 (TDP43), fused in sarcoma (FUS), superoxide dismutase 
1, huntintin, and others have been implicated in mediation of neurotoxic effects56 and are therefore potentially 
relevant therapeutic targets but have not been characterized in human brain tissue.
Materials and Methods
Regulatory Compliance. All protocols were carried out in accordance with the Charles F. and Joanne 
Knight Alzheimer’s Disease Research Center and Washington University guidelines. This specific study was 
approved by the Knight Alzheimer’s Disease Research Center tissue committee. All donors or their surrogates 
gave informed consent for their brains to be used for research studies.
Homogenization of human cortical tissue. Human frontal cortical tissue samples were obtained from 
the Knight Alzheimer’s Disease Research Center at Washington University School of Medicine in Saint Louis, 
Missouri. Cognitive status was determined with a validated retrospective postmortem interview with an inform-
ant to establish the Clinical Dementia Rating (CDR). Pathologically confirmed CDR3 cases were selected (n = 6, 
84.1+ /− 6.6 years at death, 11.4+ /− 4.8 hours post mortem interval, 4 female & 2 male). In addition, two cogni-
tively normal (CDR0, negative AD pathology) cases were selected for use in control experiments (n = 2). Frozen 
cortical samples were weighed and placed into ice-cold Phosphate-Buffered Saline (PBS) containing protease 
inhibitors (137 mM sodium chloride, 7.76 mM sodium phosphate dibasic, 2.17 mM monopotassium phosphate, 
2.7 mM potassium chloride, 2 μ g/mL aprotinin, 1 μ g/mL leupeptin) followed by removal of leptomeninges and 
apparent vasculature. The tissue was then immediately dounce homogenized in ice-cold PBS containing pro-
tease inhibitors at a 10:1 PBS volume:tissue weight ratio using a Potter-Elvehjem Teflon coated tissue grinder at 
a constant 25 manual strokes. The addition of 3-[(3-Cholamidopropyl)dimethylammonio]-1-Propanesulfonate 
(CHAPS) at a final concentration of 0.45% (w/v) was performed for experiments as detailed below.
Measurement of soluble Aβ aggregates. We adapted our previously developed40 “dimer equivalents” 
ELISA assay to a 96-well format for the quantitation of soluble Aβ aggregates during purification. The mouse 
monoclonal antibody HJ3.4 was coated to 96-well Nunc Maxisorp plates (#464718, Nalge Nunc, Rochester, NY) 
at 20 μ g/mL in carbonate buffer (35 mM sodium bicarbonate, 16 mM sodium carbonate, 3 mM sodium azide, 
pH 9.6) in 100 μ l/well overnight at 4 °C. Plates were washed 5x between steps with PBS using a BioTek EXL405 
plate washer (BioTek, Winooski, VT). The assay plates were blocked using 0.2 μ m filtered 4% BSA (#7030, 
Sigma-Aldrich, St. Louis, MO) in PBS for 1 hour at room temperature. Samples or dimer standard were added 
neat or diluted in standard diluent (0.2 μ m filtered 0.25% BSA, 0.005% Tween-20, 300 mM Tris, 3 mM sodium 
azide, 2 μ g/mL aprotinin, 1 μ g/mL leupeptin, in PBS) to 100 μ L final volume and loaded. An 8-point standard 
curve was generated using 2000, 1000, 500, 250, 125, 62.5, and 31.25 pg/mL of Aβ 1-40Ser26Cys dimer in DMSO 
(AnaSpec, Fremont, CA) diluted in standard diluent and loaded in triplicate in all experiments. All samples and 
standard were kept on ice during handling. Assay plates were incubated at 4 °C overnight. Biotinylated HJ3.4 
at 100 ng/mL was then added in PBS containing 0.2 μ m filtered 0.5% BSA plus 0.005% Tween-20 for 1 hour at 
room temperature with gentle agitation. Poly-streptavidin HRP-20 (65R-S103PHRP, Fitzgerald, Acton, MA) 
was then incubated at 30 ng/mL in PBS containing 0.2 μ m filtered 0.5% BSA plus 0.005% Tween-20 for 1 hour 
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at room temperature with gentle agitation. After a final wash, the assay was developed by addition of 3,3′ ,5,5′ 
-Tetramethylbenzidine (T5569, Sigma-Aldrich) and the absorbance was read on a BioTek Synergy 2 plate reader 
at 650 nm.
Measurement of Aβ1−x isoforms. Assessment of isoforms of Aβ starting with amino acid 1 and ending 
after the mid-domain epitope of the capture antibody (approximately amino acid 28), here termed Aβ 1−x, in the 
purification steps was determined by ELISA using the mid-domain HJ5.1 to capture and the N-terminal specific 
HJ3.4 to detect bound peptide. HJ5.1 was coated to 96-well Nunc Maxisorp plates at 20 μ g/mL in carbonate buffer 
(35 mM sodium bicarbonate, 16 mM sodium carbonate, 3 mM sodium azide, pH 9.6) in 100 μ /well overnight at 
4 °C. Plates were washed 5x between steps with PBS using a BioTek EXL405 plate washer. The assay plates were 
blocked using 0.2 μ m filtered 4% BSA in PBS for 1 hour at room temperature. Samples and standard were diluted 
in standard diluent (0.2 μ m filtered 0.25% BSA, 0.5 M guanidine-HCl, 0.005% Tween-20, 300 mM Tris, 3 mM 
sodium azide, 2 μ g/mL aprotinin, 1 μ g/mL leupeptin, in PBS) to a 100 μ L volume and loaded. An 8-point standard 
curve was generated using 2000, 1000, 500, 250, 125, 62.5, and 31.25 pg/mL of Aβ 1-40 synthetic monomer peptide 
(AnaSpec) and loaded in triplicate in all experiments. All samples and standard were kept on ice during handling. 
Assay plates were incubated at 4 °C overnight. Development of the assay was identical to the soluble Aβ aggregate 
assay as described above.
Assessment of other detergents for extraction of soluble Aβ aggregates. To determine the poten-
tial utility of common biochemical detergents for increased Aβ recovery we homogenized tissue in the presence of 
sub-critical micelle concentration detergent in PBS with protease inhibitor. The following concentrations of each 
detergent were used: sodium dodecyl sulfate (0.2% w/v), Triton™ X100 (0.018% v/v), Tween® 20 (0.007% v/v), 
6-O-(N-Heptylcarbamoyl)-methyl-α -D-glucopyranoside (Hecameg, 0.6% w/v), n-Octyl glucoside (0.55% w/v), 
CHAPS (0.45% w/v). For each tissue sample, the material was finely diced prior to homogenization to ensure each 
detergent received approximately similar quantities of input. Following centrifugation at 100,000× g RCF, the 
homogenates were diluted and the amount of soluble Aβ aggregate determined by ELISA.
Size exclusion chromatography. Analysis of the apparent molecular weight of the Aβ aggregates was 
achieved using size exclusion chromatography, which unlike most gel electrophoresis methods, does not require 
SDS or similar detergents. A maximum of 1 mL of enriched aggregate was injected onto a Superdex 200 10/300 
GL column attached to an AKTA Purifier FPLC (GE Healthcare) and eluted with PBS containing 0.2 μ m filtered 
0.05% BSA at a flow rate of 0.5 mL/min. A total of twenty-three 1 mL elution fractions were collected starting 
from the 6th mL. The eluted volume was collected in 0.2 μ m filtered 1% BSA blocked low-binding microcentri-
fuge tubes prior to further purification or analysis. Under identical conditions, we ran globular protein size stand-
ards (Biorad) included thyroglobulin (670 kDa), gamma-globulin (158 kDa), ovalbumin (44 kDa), myoglobin 
(17 kDa), and vitamin B12 (1.35 kDa).
Controls for ex vivo Aβ aggregation during CHAPS homogenization. To determine whether the 
addition of CHAPS to the purification method induces ex vivo aggregation, CDR3 derived monomer was spiked 
into cognitively normal human tissue during homogenization containing CHAPS at or below the critical micelle 
concentration. In addition, synthetic Aβ 1-42 was similarly spiked into cognitively normal human tissue during 
homogenization containing CHAPS at 0.45% v/w in PBS. The homogenate was immediately centrifuged at 
100,000× g RCF for 1 hour and the resulting supernatant applied to the soluble Aβ aggregate ELISA to measure 
the presence of any aggregates formed ex vivo. Furthermore, a 1 gram sample of cognitively normal cortex was 
homogenized with 0.45% CHAPS-PBS spiked with 2 ng/mL AD derived monomer. The homogenate was pro-
cessed using the differential centrifugation protocol as described above. The resulting concentrate was separated 
by size exclusion chromatography on the Superdex 200 10/300 GL column and the presence or absence of soluble 
Aβ aggregates was assessed in the collected fractions.
Control for ex vivo Aβ aggregation in other detergents. To determine if the typical concentrations 
of Triton X-100 (0.1–1.0%), sodium dodecyl sulfate (0.1–2.0%), and Tween20 (0.1–1.0%) results in ex vivo aggre-
gation, we spiked 2 ng of AD-derived Aβ monomer at 2 ng/mL into homogenization buffer with the appropriate 
amount of cortical tissue from a cognitively normal, AD pathology negative brain. Following homogenization 
and centrifugation at 100,000× g RCF, the supernatant was loaded onto the soluble Aβ aggregate ELISA and 
developed as described.
Reducing Aβ loss by blocking with bovine serum albumin. Non-specific loss of Aβ during multiple 
procedural steps is an additive problem. A significant reduction in nonspecific loss was achieved by incubation 
of every sample tube and micropipette tips with a solution of 0.2 μ m filtered 1% BSA in PBS. Excess BSA was 
removed by washing with molecular grade water and then the plasticware was dried prior to use. In addition, 
during size exclusion chromatography we utilized 0.2 μ m filtered 0.05% BSA in the mobile phase to reducing 
nonspecific loss to the Superdex 200 chromatography resin.
Concentration by Macrosep concentrator. High molecular weight Aβ aggregates were concentrated 
using a 100 kDa molecular weight cut off centrifugal concentrator (#MAP100C36, Pall Corporation, Port 
Washington, NY). Freshly prepared cortical homogenate was clarified at 100,000× g RCF and transferred to a 
chilled 100 kDa molecular weight cut off concentrator. The concentrator was centrifuged at 4000× g RCF at 4 °C 
until the sample was concentrated approximately 10-fold. The concentrations of soluble Aβ aggregates were deter-
mined by ELISA.
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Ammonium sulfate precipitation. Owing to the high molecular weight nature of soluble Aβ aggregates 
they can be readily precipitated by addition of ammonium sulfate. Over a period of 30 minutes an ice-cold sat-
urated solution of ammonium sulfate was added to the 100,000× g spun homogenate to a final concentration 
of 35% and then incubated on wet ice with gentle mixing for an additional 30 minutes. The precipitation was 
transferred to a series of 30 mL polypropylene centrifuge tubes and spun at 30,000× g for 30 minutes in a Sorvall 
RC5B Plus centrifuge using a SS-34 rotor operated at 4 °C. The resulting pellet was gently dissolved in ice-cold 
PBS containing protease inhibitors prior to further purification methods. To determine whether the process of 
ammonium sulfate precipitation induces ex vivo aggregation we performed a spike recovery assessment. Briefly, 
approximately 1 gram of cortical tissue from a cognitively normal participant was homogenized as described 
above with the addition of 2 ng/mL AD derived monomer. The homogenate was precipitated as described above 
and then separated by size exclusion chromatography before being assessed for Aβ 1−x and soluble Aβ aggregates 
by ELISA.
Differential ultracentrifugation for isolation of soluble Aβ aggregates from other forms of 
Aβ. The cortical homogenates were transferred to chilled 30 mL polypropylene centrifuge tubes (#3119-0030, 
Nalgene) and spun at 17,000× g for 30 minutes in a Sorvall RC5B Plus centrifuge using a SS-34 rotor at 4 °C. The 
supernatant was transferred to 26.3 mL polycarbonate tubes (#355618, Beckman Coulter) and spun at 100,000× g 
for 1 hour in a Beckman Optima XPN-100 ultracentifuge using a type 70-Ti rotor operated at 4 °C under vac-
uum. The debris pellet from the 100,000× g spin was reserved for further analysis. The resulting 100,000× g spin 
supernatant was immediately transferred to a new 26.3 mL tube and underlayed with 1 mL of sterile 70% sucrose. 
The centrifuge tube was spun at 475,000× g for 1 hour in the Beckman Optima XPN-100 with a brake setting of 
“2” to reduce disturbance of the resulting protein layers. The supernatant was carefully removed in 5 mL layers 
and then a final 2 mL layer containing the high-molecular weight soluble Aβ concentrate overlaying the sucrose 
cushion was removed.
Ion Exchange Chromatography (IEX). The binding capacity and the elution resolution of Aβ species were 
assessed using anion exchange chromatography. Attached to the AKTA Purifier, 4.7 mL HiScreen strong anion (Q 
FF, #17-5053-01, GE Healthcare) column was equilibrated with 10 mM Tris, pH 8.0 prior to sample injection. A 
sample volume of 1 mL of cortical homogenate, diluted 1:5 with 10 mM Tris pH 8.0 (Buffer A) to reduce sodium 
chloride concentration, was injected onto the column. Following sample flowthrough, a gradient was performed 
with 10 mM Tris, pH 8.0, 3 M sodium chloride (Buffer B). Fractions were collected during the full gradient and 
assessed for soluble Aβ aggregates to measure the overall binding and elution.
Hydrophobicity Interaction Chromatography (HIC). The binding capacity and the elution resolution 
of Aβ species were assessed using HIC. Attached to the AKTA Purifier, a 4.7 mL HiScreen Butyl FF (#17-1357-01, 
GE) column was equilibrated with 10 mM Tris, pH 8.0, 3 M sodium chloride prior to sample injection. A sample 
volume of 1 mL of cortical homogenate, diluted 1:5 with 10 mM Tris pH 8.0, 3 M sodium chloride (Buffer A) to 
increase the sodium chloride concentration, was injected onto the column. Following sample flow through, a 
gradient was performed with 10 mM Tris, pH 8.0 (Buffer B). Fractions were collected during the full gradient and 
assessed for soluble Aβ aggregates to measure the overall binding and elution.
Conjugation of monoclonal antibodies to cyanogen bromide (CNBr) sepharose. Immunoprecipitation 
of Aβ was performed using a combination of the N-terminal specific monoclonal, HJ3.457, and a mid-domain specific 
monoclonal, HJ5.158, conjugated to CNBr-Sepharose beads. Purified monoclonals were dialyzed against coupling 
buffer (0.1 M sodium carbonate, 0.5 M sodium chloride, pH 8.3) and then spun at 17,000× g in a table top refrigerated 
centrifuge to remove aggregated antibody complexes. One gram of activated CNBr-Sepharose was combined with 
a 6 mg equal mixture of each of the monoclonal antibodies in coupling buffer and incubated for 2 hours with gentle 
mixing. Unoccupied binding sites were blocked for 1 hour with 1 M ethanolamine, pH 8.0. The beads were rinsed with 
three cycles of 0.1 M sodium acetate, 0.5 M sodium chloride, pH 4.0 and coupling buffer to remove residual uncoupled 
protein. The beads were then washed and stored in PBS containing 0.02% sodium azide at 4 °C. All conjugation steps 
were performed at room temperature.
Immunoprecipitation (IP) of Aβ. Following isolation, Aβ was immunopurified by addition of 100 μ l dual 
antibody conjugated CNBr-Sepharose bead slurry per milliliter of concentrate in a preblocked microcentrifuge 
tube. Immunoprecipitation was allowed to occur overnight with gentle rotation (4 rpm) at 4 °C. The beads were 
isolated by centrifugation (2000× g, 2 min), and the supernatant was removed and saved for analysis. The beads 
were washed 15 times with 1 mL ice-cold PBS and gentle rotation for 2 minutes per wash. For assessment of total 
protein in each wash step the beads were washed with 0.1x PBS buffer, due to sodium chloride sensitivity with 
the NanoOrange assay. Bound Aβ was eluted by three rounds of 100 μ l of 150 mM ammonium hydroxide and 
agitation for 5 minutes each. The elution volumes were pooled into a BSA blocked microcentrifuge tube and 
neutralized with 30 μ l 3 M Tris, pH 7.2. Aliquots of the elution were removed for quantification of total protein, 
Aβ 1−x, and soluble Aβ aggregates. Aβ eluates were stored at − 80 °C or used immediately for electron microscopy.
Alternative IP elution conditions. IP was performed on a freshly prepared cortical homogenate clarified 
at 100,000× g RCF as described above. The total IP bead volume was divided into four separate tubes and then 
300 μ L of either 5 M lithium chloride, 150 mM ammonium hydroxide pH 10.5, 200 mM glycine pH 2.7, or 1x 
NuPAGE LDS buffer (#NP0008, Invitrogen) was added to the respective tube and allowed to incubate at room 
temperature, or 95 °C for the LDS buffer, for 15 minutes. The resulting eluent was removed and immediately 
run over the Superdex 200 10/300 column and fractions collected. The distribution of Aβ following elution was 
assessed by indirect ELISA using the mid-domain specific mAb HJ5.1.
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Quantification of protein during purification steps. Total protein during each step of the purifica-
tion procedure was quantitatively tracked by measurement with a colorimetric bicinchoninic acid (BCA) assay 
(#23225, ThermoFisher Scientific) using a reference BSA as the standard. Appropriate dilutions for each sample 
and the standard were combined with the assay reagent in a 96-well microplate and measured by absorbance at 
562 nm on the BioTek plate reader. Because the protein levels were below the limit of sensitivity for BCA, total 
protein quantification of the immunoprecipitation wash steps and the resulting eluate were measured using a 
fluorescence-based NanoOrange assay (#N6666, Thermofisher Scientific) using a reference BSA as the standard. 
The lower limit of quantification for the NanoOrange assay is 150 ng/mL. Appropriate dilutions for each sample 
and the standard were combined with the assay reagent in a 96-well microplate and measured by fluorescence by 
excitation at 485 nm and emission at 590 nm on the BioTek plate reader. The NanoOrange assay produces inter-
pretable results at sodium chloride concentrations of < 30 mM.
Immunoelectron microscopy. For quantification of purified amyloid aggregates, samples were absorbed 
onto glow-discharged carbon-coated 200-mesh Formvar grids (FCF200-Cu-UA, Electron Microscopy Sciences) 
by incubation of a 5 μ L volume for two minutes. Sample grids were quenched for 30 minutes with quench buffer 
(50 mM lysine, 50 mM glycine, 50 mM ammonium chloride) followed by blocking for 30 minutes with 1% bovine 
serum albumin in NaHCa buffer (100 mM sodium chloride, 30 mM HEPES, 2 mM calcium chloride, pH 7). 
Sample grids were then incubated with HJ3.4 (1 μ g/mL) in blocking solution for 1 hour. Following three washes 
with blocking solution, the grids were incubated with anti-mouse IgG conjugated to 6 nm colloidal gold (806.022, 
Aurion) diluted 1:15 in blocking solution. The grids were washed three times with NaHCa buffer followed by 
fixation in 2.5% glutaraldehyde for five minutes. The grids were negatively stained with a 1% (w/v) uranyl acetate 
solution and allowed to dry prior to imaging. All labeling steps were performed at room temperature. Images 
were collected using a JEOL JEM-1400 transmission electron microscope operating at 80 kV attached to an AMT 
XR111 high-speed pixel phosphor-scintillated 12-bit CCD camera.
Qualitative imaging using quick-freeze deep etch electron microscopy was performed according to published 
protocol, with minor modifications59. Samples were applied to acid cleaned glass chips and immunostained as 
described as above. Coverslips were rinsed in dH2O and frozen by abrupt application of the sample against a liq-
uid helium cooled copper block with a Cryopress freezing machine. Frozen samples were transferred to a liquid 
nitrogen cooled Balzers 400 vacuum evaporator, etched for 20 minutes at − 80 °C and rotary replicated with ~ 
2 nm platinum deposited from a 15° angle above the horizontal, followed by an immediate ~10 nm stabilization 
film of pure carbon deposited from an 85° angle. Replicas were floated onto a dish of concentrated hydrofluoric 
acid and transferred through several rinses of dH20 with a loopful of Photo-flo, picked up on formvar coated 
grids, and imaged on the JEOL JEM-1400 transmission electron microscope.
FIJI based quantification of immunoelectron microscopy images. For each sample, a series of ten 
random 1282 × 957 nm fields containing gold-positive material was photographed on the JEOL JEM-1400 trans-
mission electron microscope. Each image was subjected to local background subtraction followed by the creation of 
separate threshold masks for the gold particles and the surrounding aggregates. The threshold settings were stand-
ardized across all samples to reduce selection bias. To quantify the surface area of each aggregate containing at least 
1 gold particle, the Analyze Particles plugin in ImageJ60 was applied to an image stack containing both threshold 
masks to generate gold particle positive aggregate regions of interest. To quantify the number of gold particles per 
aggregate, the Analyze Particles plugin in ImageJ was again used with the same regions of interest but the (denser) 
gold intensity threshold. The analysis was entirely automated, without user input after image selection.
Statistics. All data were analyzed in Prism 7.0 (GraphPad Software, La Jolla, CA). The Shapiro-Wilk normal-
ity test was used to determine whether the distribution of the Aβ surface area measurements and gold particle 
counts were normally distributed. As the data sets displayed non-normal distributions in more than one group, 
Kruskal-Wallis ANOVA with Dunn post hoc test was used to compare groups. Spearman r correlations were per-
formed to assess the relationship between the Aβ surface area and the number of gold particles.
Ammonium acetate size exclusion chromatography. To assess the size distribution of amyloid beta 
aggregates using ammonium acetate during size exclusion chromatography, cortical tissue was homogenized 
and centrifuged at 100,000× g RCF as described above. Each sample was injected onto a Superdex 200 10/300 
column equilibrated with 50 mM ammonium acetate, pH 8.5 at 4 °C and fractions collected. Each sample was 
subsequently injected on a Superdex 200 10/300 column equilibrated with 1x PBS at 4 °C and fractions collected. 
The fractions were assessed using the Aβ dimer equivalents ELISA.
Liquid chromatography tandem mass spectrometry. Soluble Aβ aggregates were eluted from IP with 
100% formic acid and dried under vacuum. The samples were then precipitated with the 2D Clean-Up Kit (GE 
Healthcare, Piscataway, NJ) to remove residual lipids, salt and polymers leached off of the beads used for immu-
noprecipitation during elution. The precipitated protein was resuspended in 100% formic acid. Samples were then 
subjected to C8 cleanup (Glygen) to separate larger proteins from Aβ peptides. C8 eluant was dried to completeness 
under vacuum and stored at − 80 °C until analysis. Samples were resuspended in 1%/10%/5% formic acid/acetoni-
trile/methanol (v/v/v). The samples were analyzed by nanoLC-MS/MS on an Orbitrap Fusion mass spectrometer 
(ThermoFisher) in positive ion mode. Chromatographic separation was performed on an ACQUITY UPLC HSS 
T3 (360 μ m OD × 75 μ m ID) column packed with 10 cm C18 (1.8 μ m, 100 Å, Waters) at 300 nL/min and heated to 
60 °C. MS files (.raw) were imported into PEAKS (version 7.5, Waters) and searched against a UniprotKB/SwissProt 
Human database of canonical sequences (October 2015; 20,204 entries) appended with the cRAP contaminant 
database (December 2015 version, The Global Proteome Machine, www.thegpm.org/cRAP/index.html).
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